FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306290868> ?p ?o ?g. }

• W4306290868 abstract "Abstract Background In heart failure with reduced ejection fraction (HFrEF), drugs including angiotensin-converting enzyme inhibitors (ACEi)/ angiotensin receptor blockers (ARB), beta-blockers, and mineralocorticoid receptor antagonists (MRA) have been shown to have robust survival benefits. However, these guideline-recommended therapies remain underutilized in clinical practice. Frailty is common in HFrEF and may lead to underprescription of life-saving therapy. Purpose We aimed to investigate the association between physical frailty and the use of evidence-based pharmacological therapy for HFrEF, and the impact of this on prognosis Methods The FLAGSHIP study included patients hospitalized for acute HF and data on physical frailty were collected prospectively. Of the total 3,272 patients registered in the FLAGSHIP study, 1,041 HFrEF patients (70 years; 73% male) with left ventricular ejection fraction ≤40% were analyzed and were divided into 4 groups by severity of frailty: category I (n=371) [least frail], II (n=275), III (n=224), and IV (n=171) [most frail]. Results An ACEi/ARB was prescribed in 76% of category I and 53% of category IV patients; for a beta-blocker these proportions were 94% and 76%, respectively; for an MRA they were 55% and 46%, respectively. The proportion of patients using receiving all 3 drugs decreased as frailty increased, with approximately twice the rate of use of triple therapy in category I patients (40.2%) compared to category IV patients (23.4%) [p&lt;0.001] (Figure 1). In adjusted analyses, the severity of frailty was an independent predictor for non-use of an ACEi/ARB (Odds ratio (OR): 1.23, 95% CI: 1.05–1.43, per 1 category increase) and a beta-blocker (OR: 1.32, 95% CI: 1.06–1.64), but not an MRA (OR: 0.97, 95% CI: 0.84–1.12). Risk of the composite outcome of all-cause death or HF rehospitalization increased with decreasing use of treatment across frailty categories: category I-II (Hazard ratio (HR): 1.80, 95% CI: 1.08–2.98, in 0–1 drug with 3 drugs as reference) and III–IV (HR: 1.53, 95% CI: 1.01–2.32). The relationship between the number of HF drugs prescribed and the composite outcome did not differ across frailty categories (p-interaction=0.86). The HRs for all 12 groups, reflecting frailty categories and a number of HF drugs is depicted in Figure 2. The HRs for composite outcome increased with increasing frailty category and with decreasing number of drugs, with an almost 4-fold difference in risk between the least frail patients receiving all three evidence-based therapies and the most frail receiving only 0–1 drug. Conclusions Prescription of guideline-recommended therapy decreased as the severity of frailty increased in patients with HFrEF. Sub-optimal medical therapy was associated with a worse outcome and underprescription of guideline-recommended therapy may contribute to the poor prognosis associated with frailty. An effective strategy is needed to improve the medical treatment of frail patients with HFrEF. Funding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): This study issupported by a Grant-in-Aid for Scientifi c Research (A) from the Japan Society for the Promotion of Science (16H01862). ToruKondo receives grants from the Uehara Memorial Foundation and the Japanese Heart Failure Society Tsuchiya Foundation forthe research activities at the University of Glasgow." @default.
• W4306290868 created "2022-10-15" @default.
• W4306290868 creator A5035156629 @default.
• W4306290868 creator A5039492344 @default.
• W4306290868 creator A5046106438 @default.
• W4306290868 creator A5049126967 @default.
• W4306290868 creator A5056907262 @default.
• W4306290868 creator A5070122034 @default.
• W4306290868 creator A5072605248 @default.
• W4306290868 creator A5075334695 @default.
• W4306290868 date "2022-10-01" @default.
• W4306290868 modified "2023-09-26" @default.
• W4306290868 title "Frailty and use of treatment in patients with heart failure and reduced ejection fraction" @default.
• W4306290868 doi "https://doi.org/10.1093/eurheartj/ehac544.965" @default.
• W4306290868 hasPublicationYear "2022" @default.
• W4306290868 type Work @default.
• W4306290868 citedByCount "0" @default.
• W4306290868 crossrefType "journal-article" @default.
• W4306290868 hasAuthorship W4306290868A5035156629 @default.
• W4306290868 hasAuthorship W4306290868A5039492344 @default.
• W4306290868 hasAuthorship W4306290868A5046106438 @default.
• W4306290868 hasAuthorship W4306290868A5049126967 @default.
• W4306290868 hasAuthorship W4306290868A5056907262 @default.
• W4306290868 hasAuthorship W4306290868A5070122034 @default.
• W4306290868 hasAuthorship W4306290868A5072605248 @default.
• W4306290868 hasAuthorship W4306290868A5075334695 @default.
• W4306290868 hasBestOaLocation W43062908681 @default.
• W4306290868 hasConcept C126322002 @default.
• W4306290868 hasConcept C142724271 @default.
• W4306290868 hasConcept C164705383 @default.
• W4306290868 hasConcept C27016395 @default.
• W4306290868 hasConcept C2778198053 @default.
• W4306290868 hasConcept C2780182762 @default.
• W4306290868 hasConcept C71924100 @default.
• W4306290868 hasConcept C78085059 @default.
• W4306290868 hasConcept C84393581 @default.
• W4306290868 hasConceptScore W4306290868C126322002 @default.
• W4306290868 hasConceptScore W4306290868C142724271 @default.
• W4306290868 hasConceptScore W4306290868C164705383 @default.
• W4306290868 hasConceptScore W4306290868C27016395 @default.
• W4306290868 hasConceptScore W4306290868C2778198053 @default.
• W4306290868 hasConceptScore W4306290868C2780182762 @default.
• W4306290868 hasConceptScore W4306290868C71924100 @default.
• W4306290868 hasConceptScore W4306290868C78085059 @default.
• W4306290868 hasConceptScore W4306290868C84393581 @default.
• W4306290868 hasIssue "Supplement_2" @default.
• W4306290868 hasLocation W43062908681 @default.
• W4306290868 hasOpenAccess W4306290868 @default.
• W4306290868 hasPrimaryLocation W43062908681 @default.
• W4306290868 hasRelatedWork W2051712573 @default.
• W4306290868 hasRelatedWork W2052242574 @default.
• W4306290868 hasRelatedWork W2077083067 @default.
• W4306290868 hasRelatedWork W2091139515 @default.
• W4306290868 hasRelatedWork W2319805938 @default.
• W4306290868 hasRelatedWork W2355594703 @default.
• W4306290868 hasRelatedWork W2622922034 @default.
• W4306290868 hasRelatedWork W3033076790 @default.
• W4306290868 hasRelatedWork W3155674270 @default.
• W4306290868 hasRelatedWork W3187572025 @default.
• W4306290868 hasVolume "43" @default.
• W4306290868 isParatext "false" @default.
• W4306290868 isRetracted "false" @default.
• W4306290868 workType "article" @default.